The gene therapy journey for hemophilia: are we there yet?
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Since the isolation and characterization of the genes for FVIII and FIX some 30 years ago, a longstanding goal of the field has been development of successful gene therapy for the hemophilias. In a landmark study published in 2011, Nathwani et al demonstrated successful conversion of severe hemophilia B to mild or moderate disease in 6 adult males who underwent intravenous infusion of an adeno-associated viral (AAV) vector expressing factor IX. These 6 subjects have now exhibited expression of FIX at levels ranging from 1% to 6% of normal for periods of > 2 years. This review discusses obstacles that were overcome to reach this goal and the next steps in clinical investigation. Safety issues that will need to be addressed before more widespread use of this approach are discussed. Efforts to extend AAV-mediated gene therapy to hemophilia A, and alternate approaches that may be useful for persons with severe liver disease, who may not be candidates for gene transfer to liver, are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citation
Research works printed but not linked: 34
- Nathwani, 2011, Adeno-associated viral vector mediated gene transfer for hemophilia B., Blood, 118, 4, 10.1182/blood.V118.21.5.5 · DOI
- Shapiro, 2012, Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients., Blood, 119, 666, 10.1182/blood-2011-07-367003 · DOI · Paper page
- Ostergaard, 2011, Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide., Blood, 118, 2333, 10.1182/blood-2011-02-336172 · DOI · Paper page
- Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency., N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI · Paper page
- Herzog, 1998, Long-term phenotypic correction of hemophilia B in a large animal model by AAV-mediated gene transfer., Blood, 92, 153a
- Boyce, 2001, Trial halted after gene shows up in semen., Nature, 414, 677, 10.1038/414677a · DOI
- Arruda, 2001, Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males., Mol Ther, 4, 586, 10.1006/mthe.2001.0491 · DOI · Paper page
- Favaro, 2009, Host and vector-dependent effects on the risk of germline transmission of AAV vectors., Mol Ther, 17, 1022, 10.1038/mt.2009.56 · DOI · Paper page
- Schuettrumpf, 2006, Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial., Mol Ther, 13, 1064, 10.1016/j.ymthe.2006.03.002 · DOI
- Berns, 2007, Parvoviridae.
- Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses., J Infect Dis, 199, 381, 10.1086/595830 · DOI · Paper page
- Nathwani, 2007, Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates., Blood, 109, 1414, 10.1182/blood-2006-03-010181 · DOI · Paper page
- Sommer, 2003, Quantification of adeno-associated virus particles and empty capsids by optical density measurement., Mol Ther, 7, 122, 10.1016/S1525-0016(02)00019-9 · DOI · Paper page
- Finn, 2010, Factor IX-R338L (FIX Padua) as a novel alternative for the treatment of canine severe hemophilia B., Mol Ther, 18, S239, 10.1016/S1525-0016(16)38056-X · doi:10.1016/s1525-0016(16)38056-x
- Rutledge, 1997, Adeno-associated virus vector integration junctions., J Virol, 71, 8429, 10.1128/JVI.71.11.8429-8436.1997 · DOI · Paper page
- Nakai, 1999, Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver., J Virol, 73, 5438, 10.1128/JVI.73.7.5438-5447.1999 · DOI · Paper page
- Donsante, 2001, Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors., Gene Ther, 8, 1343, 10.1038/sj.gt.3301541 · DOI · Paper page
- Li, 2011, Assessing the potential for AAV vector genotoxicity in a murine model., Blood, 117, 3311, 10.1182/blood-2010-08-302729 · DOI · Paper page
- Chao, 2000, Sustained expression of human factor VIII in mice using a parvovirus-based vector., Blood, 95, 1594, 10.1182/blood.V95.5.1594.005k34_1594_1599 · DOI · Paper page
- Jiang, 2006, Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs., Blood, 108, 107, 10.1182/blood-2005-12-5115 · DOI · Paper page
- Sabatino, 2011, Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors., Mol Ther, 19, 442, 10.1038/mt.2010.240 · DOI · Paper page
- Ward, 2011, Codon optimization of human factor VIII cDNAs leads to high-level expression., Blood, 117, 798, 10.1182/blood-2010-05-282707 · DOI · Paper page
- Montgomery, 2010, Alternative strategies for gene therapy of hemophilia., Hematology Am Soc Hematol Educ Program, 2010, 197, 10.1182/asheducation-2010.1.197 · DOI
- Greene, 2010, In vivo efficacy of platelet-delivered, high specific activity factor VIII variants., Blood, 116, 6114, 10.1182/blood-2010-06-293308 · DOI · Paper page
- Sun, 2008, Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX., Blood, 112, 4532, 10.1182/blood-2008-01-131417 · DOI · Paper page
- Herzog, 1999, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector., Nat Med, 5, 56, 10.1038/4743 · DOI · Paper page
- Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B., Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
- Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector., Nat Genet, 24, 257, 10.1038/73464 · DOI · Paper page
- Yarovoi, 2003, Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment., Blood, 102, 4006, 10.1182/blood-2003-05-1519 · DOI · Paper page
- Shi, 2006, Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies., J Clin Invest, 116, 1974, 10.1172/JCI28416 · DOI · Paper page
- Matsui, 2011, A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A., Mol Ther, 19, 723, 10.1038/mt.2010.290 · DOI · Paper page
- Brown, 2007, In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance., Blood, 109, 2797, 10.1182/blood-2006-10-049312 · DOI · Paper page
- Mates, 2009, Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates., Nat Genet, 41, 753, 10.1038/ng.343 · DOI · Paper page
- Hedner, 2012, Activated factor VII: my story., Haemophilia, 18, 147, 10.1111/j.1365-2516.2012.02753.x · doi:10.1111/j.1365-2516.2012.02753.x
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Self-citationTet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
“It has previously been reported that individuals with prior exposure to an antigen mount considerable immune response upon re-exposure.(23) In previous human AAV trials and NHP studies,(24) subjects that had preexisting NAb generally had higher NAb levels post-injection compared to subjects that did not.”
BackgroundRosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58
Sen, D., Gadkari, R. A., Sudha, G., Gabriel, N., Kumar, Y. S., Selot, R., Samuel, R., Rajalingam, S., Ramya, V., Nair, S. C., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.195 · Cited by 51
Metadata
- Authors
- High, K. A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-11-29
- Volume
- 120
- Issue
- 23
- Pages
- 4482-4487
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2166705256
- Cited by
- 55
- References
- 25
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The gene therapy journey for hemophilia: are we there yet? https://app.cochat.ai/papers/10.1182/blood-2012-05-423210
- The paper
- High, K. A. (2012). The gene therapy journey for hemophilia: are we there yet? Blood. https://doi.org/10.1182/blood-2012-05-423210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.